We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mayo and LipoScience in Collaboration

By Labmedica staff writers
Posted on 24 Aug 2005
A collaborative agreement between Mayo Clinic's Department of Laboratory Medicine and Pathology (Rochester, MN, USA) and LipoSciences (Raleigh, NC, USA) has been announced, whereby the Mayo Clinic will validate the clinical utility of the nuclear magnetic resonance (NMR) LipoProfile test of LipoSciences as a tool to measure cardiovascular risks.

As part of its assessment, Mayo researchers will determine the value of the NMR LipoProfile test independently and as part of its novel cardiovascular risk marker panel, a group of emerging risk factors used to aid doctors in the assessments of their patients' risks for developing cardiovascular disease or experiencing a cardiovascular event such as a stroke.

The NMR LipoProfile is a simple blood test used by doctors to directly measure the number of atherogenic low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) particles as well as protective high-density lipoprotein (HDL) particles. More...
Measuring the numbers of "bad” lipoprotein particles (LDL-P) has been found to provide a better indication of the risk of coronary heart disease than measuring the level of "bad” cholesterol.

"Mayo Clinic is widely recognized as a leader in assessing novel technologies that have the potential to significantly impact medical decisions and patient management,” explained Richard O. Brajer, president and chief executive officer at LipoScience, Inc. "We believe a preeminent institution such as Mayo Clinic will generate additional independent clinical data further confirming the clinical value of the NMR LipoProfile test.”




Related Links:
Mayo Medical Laboratories
LipoScience

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.